Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celtura Dose-Ranging Study in Japanese Pediatric Subjects
NCT01000207Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Primary completion
- Dec 2009
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of adjuvanted cell-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine in influenza A H1N1 infection (H1N1), sponsored by Novartis. Started Oct 2009; status: completed.
02
Drugs
adjuvanted cell-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT01000207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000207.